LFSC F/m Emerald Life Sciences Innovation ETF
ETFETF quote, holdings, sector allocation, technicals, and options analytics. Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
F/m Emerald Life Sciences Innovation ETF (LFSC) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2024-10-30
- Has Options
- No
- Expense ratio
- 0.54% prospectus, filed Jan 5, 2026
- Assets
- $105M SEC filing, May 31, 2026
- Trailing yield
- —
- Average daily volume
- $120K 30 sessions
- Holdings
- 40 top 10 are 53.9%
- Listed
- Oct 30, 2024 Nasdaq
Moves with. Small caps over large (18% of its variance, beta 1.00); US large-cap stocks (16% of its variance, beta 0.64); Value over growth (7% of its variance, beta -0.40); Long Treasuries (4% of its variance, beta 0.39). These factors explain 47% of its daily moves over the last year.
Stated objective. The investment objective of the F/m Emerald Life Sciences Innovation ETF (the Fund) is to seek long-term capital appreciation. (from the fund's prospectus)
All 40 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs
- May 2026
- −$129K latest reported month
- Latest 3 months
- +$1.2M +1.1% of assets
- Latest 12 months
- +$14M +13.6% of assets
View as a table
| Month | Net flow |
|---|---|
| May 2026 | −$129K |
| Apr 2026 | −$18K |
| Mar 2026 | +$1.3M |
| Feb 2026 | +$4.3M |
| Jan 2026 | −$991K |
| Dec 2025 | +$3.1M |
| Nov 2025 | +$3.1M |
| Oct 2025 | +$938K |
| Sep 2025 | +$575K |
| Aug 2025 | +$250K |
| Jul 2025 | +$1.7M |
| Jun 2025 | +$34K |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 20 months ago
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| HELXFranklin Genomic Advancements ETF | 16% | 0.50% | $35M | +26.9% | compare |
| PTHInvesco Exchange-Traded Fund Trust Invesco Dorsey Wright Healthcare Momentum ETF | 15% | 0.60% | $292M | +25.6% | compare |
| SBIOALPS Medical Breakthroughs ETF | 15% | 0.50% | $188M | +26.1% | compare |
| XBIState Street SPDR S&P Biotech ETF | 14% | 0.35% | $10.4B | +38.7% | compare |
| SPITF/m Emerald Special Situations ETF | 13% | 0.89% | $29M | +9.3% | compare |
Ranked by how much of the two portfolios is the same securities.
- Holdings vs fair value
- +5.0% 45% under, 16% over · 99% covered
- Price / earnings
- — 65% loss-making · 96% covered
- Price / book · sales
- 5.3 · 6.5 revenue growth +11.7%
- Above 200-day average
- 64% 35% above 50-day · by weight
- Short interest
- 14.6% of float, weighted · 7.3 days to cover
- Insider buying
- 5% of weight had net insider buying, 90 days; 69% net selling
- 13F holders
- +13.2% change in shares held by institutions, latest quarter
- Reporting earnings
- 10.0% of weight in 7 days; 79.1% in 14
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | KALVKalVista Pharmaceuticals Inc | 3.81% | — | — |
| New position | MANEVeraDermics Inc | — | 3.42% | — |
| Increase | CORTCorcept Therapeutics Inc | 1.52% | 4.79% | +75.8% |
| Decrease | WaVe Life Sciences Ltd | 4.21% | 0.95% | −48.2% |
| New position | DNTHDianthus Therapeutics Inc | — | 3.09% | — |
| Increase | TVTXTravere Therapeutics Inc | 4.63% | 7.67% | +13.2% |
| Increase | TMDXTransMedics Group Inc | 5.26% | 2.68% | +19.1% |
| Exit | ACADACADIA Pharmaceuticals Inc | 2.44% | — | — |
| New position | VRDNViridian Therapeutics Inc | — | 2.23% | — |
| Exit | COLLCollegium Pharmaceutical Inc | 2.06% | — | — |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| TVTX | Travere Therapeutics Inc | 7.67% | Equity (common) | US |
| COGT | Cogent Biosciences Inc | 7.53% | Equity (common) | US |
| — | LivaNova PLC | 7.11% | Equity (common) | GB |
| SYRE | Spyre Therapeutics Inc | 6.41% | Equity (common) | US |
| GH | Guardant Health Inc | 5.52% | Equity (common) | US |
| MIRM | Mirum Pharmaceuticals Inc | 4.92% | Equity (common) | US |
| CORT | Corcept Therapeutics Inc | 4.79% | Equity (common) | US |
| UTHR | United Therapeutics Corp | 4.16% | Equity (common) | US |
| MANE | VeraDermics Inc | 3.42% | Equity (common) | US |
| SVRA | Savara Inc | 3.22% | Equity (common) | US |
| CYTK | Cytokinetics Inc | 3.16% | Equity (common) | US |
| NKTR | Nektar Therapeutics | 3.14% | Equity (common) | US |
| TRVI | Trevi Therapeutics Inc | 3.12% | Equity (common) | US |
| DNTH | Dianthus Therapeutics Inc | 3.09% | Equity (common) | US |
| AXSM | Axsome Therapeutics Inc | 2.84% | Equity (common) | US |
| BLLN | Billiontoone Inc | 2.73% | Equity (common) | US |
| TMDX | TransMedics Group Inc | 2.68% | Equity (common) | US |
| VRDN | Viridian Therapeutics Inc | 2.23% | Equity (common) | US |
| ICUI | ICU Medical Inc | 2.09% | Equity (common) | US |
| CRVS | Corvus Pharmaceuticals Inc | 1.95% | Equity (common) | US |
| PVLA | Palvella Therapeutics Inc | 1.95% | Equity (common) | US |
| CBLL | Ceribell Inc | 1.55% | Equity (common) | US |
| GMED | Globus Medical Inc | 1.27% | Equity (common) | US |
| XERS | Xeris Biopharma Holdings Inc | 1.22% | Equity (common) | US |
| BBIO | Bridgebio Pharma Inc | 1.17% | Equity (common) | US |
| ITGR | Integer Holdings Corp | 1.14% | Equity (common) | US |
| TWST | Twist Bioscience Corp | 1.14% | Equity (common) | US |
| RBIL | F/m Ultrashort Treasury Inflat | 1.08% | Equity (common) | US |
| WAY | Waystar Holding Corp | 1.05% | Equity (common) | US |
| — | WaVe Life Sciences Ltd | 0.95% | Equity (common) | SG |
| HNGE | Hinge Health Inc | 0.94% | Equity (common) | US |
| KRRO | Korro Bio Inc | 0.80% | Equity (common) | US |
| RDNT | RadNet Inc | 0.79% | Equity (common) | US |
| AVAH | Aveanna Healthcare Holdings In | 0.72% | Equity (common) | US |
| LMRI | Lumexa Imaging Holdings Inc | 0.70% | Equity (common) | US |
| INSM | Insmed Inc | 0.62% | Equity (common) | US |
| ATEC | Alphatec Holdings Inc | 0.57% | Equity (common) | US |
| NEO | NeoGenomics Inc | 0.43% | Equity (common) | US |
| ALMR | Alamar Biosciences Inc | 0.18% | Equity (common) | US |
| — | U.S. Bank Money Market Deposit Account | 0.00% | Short-term investment | US |
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 10.09% | -1.60% | 4.25% |
| Feb | -- | -4.98% | 0.15% | -2.42% |
| Mar | -- | -3.63% | -3.70% | -3.67% |
| Apr | -- | 5.12% | 8.89% | 7.01% |
| May | -- | -1.11% | 3.24% | 1.06% |
| Jun | -- | 4.96% | 17.03% | 11.00% |
| Jul | -- | -0.50% | 0.10% | -0.20% |
| Aug | -- | 14.09% | 0.38% | 7.24% |
| Sep | -- | 5.75% | -2.47% | 1.64% |
| Oct | 0.00% | 11.42% | -1.95%* | 3.16% |
| Nov | 4.61% | 17.41% | -- | 11.01% |
| Dec | -11.21% | -1.65% | -- | -6.43% |
| Total | -7.12% | 69.89% | 19.97% | 27.58% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: LFSC
Executive Summary
Overall Assessment: NEUTRAL (confidence level 6/10)
Key Drivers and Primary Risks:
- Technical momentum is moderate, with RSI in neutral territory
- Volatility remains above average, driven by market amplification
- No recent news available, which could impact stock sentiment
Investment Thesis: LFSC is a moderately volatile stock with a strong correlation to the broader market. The current technical setup suggests a range-bound environment, while the lack of recent news adds uncertainty.
Recent News Sentiment Impact: Since there are no recent news headlines available, we cannot assess their impact on the stock's sentiment.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): RANGE-BOUND
- Long-term (3-12 months): BULLISH
Support/Resistance Levels:
- SMA 20: $47.19 (support)
- SMA 50: $45.90 (resistance)
- Upper Bollinger Band: $48.58 (resistance)
Momentum Signals:
- RSI interpretation: NEUTRAL (55.18) with no clear buy or sell signal
- MACD signal: BULLISH (0.73 above -0.08)
- Bollinger Bands position: NEUTRAL (price touching middle band)
Volume Analysis:
- Volume SMA 20: 3580.13 (moderate volume)
- OBV: -144759.58 (bearish on-balance volume)
- Volume Rate of Change: 54.51% (increasing volume momentum)
News & Sentiment Analysis
Recent Headlines Summary: No recent news available.
Sentiment Assessment: NEUTRAL (due to lack of recent news)
Catalyst Identification: No upcoming events or earnings dates available.
Market Narrative: The market's narrative is uncertain due to the lack of recent news, which could impact LFSC's sentiment.
Risk & Volatility Assessment
Beta Interpretation: Above average volatility with a beta of 1.19 (vs SPY).
Volatility Regime: Above average volatility driven by market amplification.
Options Market Signals:
- IV Premium vs HV30: N/A (positive = implied richer than realized)
Downside Protection: SMA 20 at $47.19 provides some support, but the lack of recent news adds uncertainty.
Market Context & Positioning
Sector Performance: No sector information available.
Institutional Activity: No institutional activity data available.
Correlation Analysis: Correlation with market is high (0.56), indicating amplification.
Relative Valuation: LFSC is trading within a range, making it difficult to determine its relative value.
Key Levels & Action Items
- Critical Price Levels: SMA 20 at $47.19 and SMA 50 at $45.90
- Breakout/Breakdown Levels: Upper Bollinger Band at $48.58 and Lower Bollinger Band at $45.79
- Time-Sensitive Catalysts: No upcoming events or earnings dates available.
- Risk Management: Stop-loss levels and position sizing considerations are uncertain due to the lack of recent news.
By providing a comprehensive analysis using the specific data above, we can help investors make informed decisions about their investment in LFSC.
LFSC Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Above average volatility - stock moves with market amplification
LFSC Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics Inc | 7.67% | $52.58 | +0.54% | -1.30% | -12.12% |
| COGT | Cogent Biosciences Inc | 7.53% | $31.43 | +0.61% | +11.65% | +0.06% |
| SYRE | Spyre Therapeutics Inc | 6.41% | $92.95 | +1.70% | +18.21% | +5.42% |
| GH | Guardant Health Inc | 5.52% | $166.66 | +2.50% | +2.25% | -5.47% |
| MIRM | Mirum Pharmaceuticals Inc | 4.92% | $83.44 | -1.92% | +4.35% | -6.58% |
| CORT | Corcept Therapeutics Inc | 4.79% | $116.28 | -0.15% | +0.04% | +2.96% |
| UTHR | United Therapeutics Corp | 4.16% | $563.49 | +1.74% | +4.34% | +15.13% |
| MANE | VeraDermics Inc | 3.42% | $136.66 | +7.51% | +20.44% | +18.03% |
| SVRA | Savara Inc | 3.22% | $4.67 | -1.89% | -1.89% | -6.60% |
| CYTK | Cytokinetics Inc | 3.16% | $62.86 | -1.70% | -0.90% | -4.48% |
| NKTR | Nektar Therapeutics | 3.14% | $38.27 | -2.42% | +3.74% | -33.63% |
| TRVI | Trevi Therapeutics Inc | 3.12% | $12.77 | -0.47% | +5.89% | -11.69% |
| DNTH | Dianthus Therapeutics Inc | 3.09% | $78.1 | -0.83% | +4.47% | -16.42% |
| AXSM | Axsome Therapeutics Inc | 2.84% | $156.31 | -2.05% | -3.64% | -19.20% |
| BLLN | Billiontoone Inc | 2.73% | $104.67 | +1.13% | +6.94% | -8.52% |
| TMDX | TransMedics Group Inc | 2.68% | $72.4 | -3.14% | -4.13% | -16.78% |
| VRDN | Viridian Therapeutics Inc | 2.23% | $23.01 | +2.59% | +25.19% | +7.37% |
| ICUI | ICU Medical Inc | 2.09% | $160.84 | -0.15% | -1.14% | -1.52% |
| CRVS | Corvus Pharmaceuticals Inc | 1.95% | $10.05 | -1.76% | +7.14% | -19.86% |
| PVLA | Palvella Therapeutics Inc | 1.95% | $126.58 | +2.15% | +3.26% | -15.37% |
| CBLL | Ceribell Inc | 1.55% | $27.14 | -1.95% | +2.92% | +14.90% |
| GMED | Globus Medical Inc | 1.27% | $78.68 | -0.35% | +3.11% | +6.38% |
| XERS | Xeris Biopharma Holdings Inc | 1.22% | $10.79 | -3.10% | +10.39% | +24.54% |
| BBIO | Bridgebio Pharma Inc | 1.17% | $67.74 | +0.28% | +4.31% | +3.09% |
| ITGR | Integer Holdings Corp | 1.14% | $126.7 | +0.00% | +0.07% | +0.30% |
| TWST | Twist Bioscience Corp | 1.14% | $149.13 | +4.51% | +0.65% | -5.91% |
| RBIL | F/m Ultrashort Treasury Inflat | 1.08% | $49.96 | +0.06% | -0.27% | +0.23% |
| WAY | Waystar Holding Corp | 1.05% | $28.84 | +0.10% | +7.33% | +16.48% |
| HNGE | Hinge Health Inc | 0.94% | $112 | +4.18% | +6.67% | +21.37% |
| KRRO | Korro Bio Inc | 0.80% | $9.29 | -1.59% | +4.62% | -5.49% |
| RDNT | RadNet Inc | 0.79% | $68.41 | -1.78% | -1.08% | -6.56% |
| AVAH | Aveanna Healthcare Holdings In | 0.72% | $12.99 | +1.88% | +5.10% | +1.56% |
| LMRI | Lumexa Imaging Holdings Inc | 0.70% | $10.81 | +1.22% | +2.37% | +6.61% |
| INSM | Insmed Inc | 0.62% | $94.04 | -1.70% | -3.83% | -20.53% |
| ATEC | Alphatec Holdings Inc | 0.57% | $10.86 | +0.00% | +4.02% | +8.28% |
| NEO | NeoGenomics Inc | 0.43% | $17.04 | +2.53% | +0.95% | -7.19% |
| ALMR | Alamar Biosciences Inc | 0.18% | $31.45 | +11.68% | +23.97% | -2.15% |